An advanced treatment for skin cancer that combines immunotherapy and mRNA vaccine technology has shown promising outcomes in a recent trial, according to a press release from pharmaceutical companies Merck and Moderna on Wednesday. The new therapy, known as intismeran, demonstrated superior results compared to immunotherapy alone in reducing melanoma recurrence and preventing cancer spread in patients who had undergone prior melanoma surgery.
The companies reported that the trial results for intismeran indicated significant improvements both statistically and in clinical terms. However, healthcare professionals expressed cautious optimism as the Phase 3 trial, the final phase before seeking regulatory approval, is still ongoing, and the results shared are from an interim analysis.
Dr. Marcus Butler, a medical oncologist at Toronto’s Princess Margaret Cancer Centre, described the announcement as a significant advancement for the field. He highlighted that the positive results observed in the larger Phase 3 trial build upon the promising outcomes seen in the Phase 2 study with a smaller patient cohort.
While awaiting the full trial data, Dr. Ramy Saleh, an oncology associate professor at McGill University in Montreal, indicated that it may take over eight months for the treatment to become available in Canada if the final trial results confirm the initial success. Saleh emphasized the challenges in scaling up a novel treatment globally and addressing the associated logistical and operational hurdles.
The treatment integrates Merck’s immunotherapy drug Keytruda with a personalized mRNA vaccine from Moderna, targeting specific mutations identified in patients’ tumors. Immunotherapy enhances the immune system by removing its inhibitory mechanisms, while mRNA vaccines provide instructions to assist the immune system in combating cancer cells.
Dr. Lennard Lee, a medical oncologist and associate professor in Oxford, explained that the treatment leverages tumor samples to identify abnormal proteins (neoantigens) in cancer cells. Subsequently, an mRNA vaccine developed from individual tumor samples trains the immune system to recognize and attack cancer cells containing these antigens.
Despite the positive outcomes, concerns and limitations exist. The trial involved 1,137 high-risk melanoma patients, including Canadian participants, who received Keytruda with the personalized vaccine or Keytruda alone. One issue raised by Dr. Butler is the potential immune stimulation from mRNA vaccines, which could affect the interpretation of results. Additionally, the trial focused solely on early-stage melanoma patients, necessitating further research for later-stage cases.
In conclusion, the integration of immunotherapy and mRNA vaccine technology in treating melanoma shows promising potential, but ongoing research is crucial to determine its effectiveness in broader patient populations and disease stages.